年龄相关性黄斑变性中地图样萎缩的进展:AREDS2报告16
AREDS2前瞻性队列分析显示,基线时6.2%眼存在地图样萎缩(GA),平均随访4.4年期间17.3%眼新发GA;GA扩大速率约0.29 mm/年,受病灶特征和基因型影响,与AREDS2治疗分配无关。
要点
- 基线GA患病率6.2%,5年新发GA的Kaplan-Meier率为19%。
- 新发GA眼4年内进展为新生血管AMD的风险为29%。
- 非中心性GA眼4年内中心受累风险为57%。
核心结论
- GA扩大持续存在并导致快速中心视力丧失,扩大速率受病灶特征和基因型影响,与AREDS2治疗分配无关。
研究设计与样本
- AREDS2随机对照试验中的前瞻性队列研究,纳入50-85岁参与者,基线及每年评估立体彩色眼底照片。
主要发现
- 基线时517眼(6.2%)有预先存在的GA但不伴新生血管AMD;6530眼有风险,平均随访4.4年中1099眼(17.3%)新发GA。
- 新发GA眼后续4年新生血管AMD风险为29%;新发非中心性GA眼4年中心受累风险为57%。
- 预先存在GA眼扩大速率为0.29 mm/年(95%CI 0.27-0.30),新发GA眼为0.28 mm/年(95%CI 0.27-0.30)。
- 合并组中,非中心性、多灶性、中等基线大小和双侧GA与更快的扩大显著相关(交互作用P<0.0001);AREDS2治疗分配(P=0.33)和吸烟状态(P=0.05)无显著影响。
- ARMS2风险(P<0.0001)、C3非风险(P=0.0002)和APOE非风险(P=0.001)基因型与更快的扩大显著相关。
临床怎么用
- 临床可依据GA病灶特征(非中心性、多灶性、中等大小、双侧)和基因型评估扩大风险,并监测新生血管AMD和中心受累。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the prevalence, incidence, and clinical characteristics of eyes with geographic atrophy (GA) in age-related macular degeneration (AMD), including clinical and genetic factors affecting enlargement. DESIGN: Prospective cohort study within a controlled clinical trial. PARTICIPANTS: Age-Related Eye Disease Study 2 (AREDS2) participants, aged 50-85 years. METHODS: Baseline and annual stereoscopic color fundus photographs were evaluated for GA presence and area. Analyses included GA prevalence and incidence rates, Kaplan-Meier rates, mixed-model regression, and multivariable analysis of the square root of GA, area adjusted for covariates, including clinical/imaging characteristics and genotype. MAIN OUTCOME MEASURES: (1) Presence or development of GA; (2) change in the square root of GA area over time. RESULTS: At baseline, 517 eyes (6.2%) of 411 participants (9.8%) had pre-existing GA (without neovascular AMD), with the following characteristics: 33% central, 67% noncentral; and the following configurations: 36% small, 26% solid/unifocal, 24% multifocal, 9% horseshoe/ring, and 6% indeterminate. Of the remaining 6530 eyes at risk, 1099 eyes (17.3%) of 883 participants developed incident GA without prior neovascular disease during mean follow-up of 4.4 years. The Kaplan-Meier rate of incident GA was 19% of eyes at 5 years. In eyes with incident GA, 4-year risk of subsequent neovascular AMD was 29%. In eyes with incident noncentral GA, 4-year risk of central involvement was 57%. GA enlargement rate (following square root transformation) was similar in eyes with pre-existing GA (0.29 mm/year; 95% confidence interval 0.27-0.30) and incident GA (0.28 mm/year; 0.27-0.30). In the combined group, GA enlargement was significantly faster with noncentrality, multifocality, intermediate baseline size, and bilateral GA (P < 0.0001 for interaction in each case) but not with AREDS2 treatment assignment (P = 0.33) or smoking status (P = 0.05). Enlargement was significantly faster with ARMS2 risk (P < 0.0001), C3 non-risk (P = 0.0002), and APOE non-risk (P = 0.001) genotypes. CONCLUSIONS: Analyses of AREDS2 data on natural history of GA provide representative data on GA evolution and enlargement. GA enlargement, which was influenced by lesion features, was relentless, resulting in rapid central vision loss. The genetic variants associated with faster enlargement were partially distinct from those associated with risk of incident GA. These findings are relevant to further investigations of GA pathogenesis and clinical trial planning.
引用
- Keenan TD, Agrón E, Domalpally A, et al. Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16. Ophthalmology. 2018. PMID: 30060980. doi:10.1016/j.ophtha.2018.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。